Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries
By H. Getahun, A. Matteelli, I. Abubakar, M. Aziz, A. Baddeley, D. Barreira, Saskia den Boon, S. Borroto Gutiérrez, J. Bruchfeld, Erlina Burhan and 62 more. European Respiratory Journal, 2015
598 citations recorded by the source corpus.
Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses to previously acquired Mycobacterium tuberculosis infection without clinical evidence of active tuberculosis (TB). Here we report evidence-based guidelines from the World Health Organization for a public health approach to the management of LTBI in high risk individuals in countries with high or middle upper income and TB incidence of <100 per 100 000 per year. The guidelines strongly recommend systematic testing and treatment of LTBI in people living with HIV, adult and child contacts of pulmonary TB cases, patients initiating anti-tumour necrosis factor treatment, patients receiving dialysis, patients preparing for organ or haematological transplantation, and patients with silicosis. In prisoners, healthcare workers, immigrants from high TB burden countries, homeless persons and illicit drug users, systematic testing and treatment of LTBI is conditionally recommended, according to TB epidemiology and resource availability. Either commercial interferon-gamma release assays or Mantoux tuberculin skin testing could be used to test for LTBI. Chest radiography should be performed before LTBI treatment to rule out active TB disease. Recommended treatment regimens for LTBI include: 6 or 9 month isoniazid; 12 week rifapentine plus isoniazid; 3–4 month isoniazid plus rifampicin; or 3–4 month rifampicin alone. Guidelines on LTBI for low TB incidence countries – essential element of the @WHO #EndTB strategy and TB elimination http://ow.ly/RW8xn
Subfields: Epidemiology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/a17ddea94d8162163c76a0a1546b74b4b5e4ad41
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
Citations in the corpus
- KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. (2020, background): “If the patient is determined to have latent TB, there are several treatment regimens that can be used.(309,315,316) There is no consensus as to the duration of treatment that needs to be completed prior to transplantation; however, it is reasonable that once the patient is clinically tolerating the ”